Today, CDK4/6 inhibitors in combination with hormone therapy have become the reference treatment in first-line metastatic HR+ HER2- breast cancer, based on published clinical data on efficacy and survival.
Today, CDK4/6 inhibitors in combination with hormonal therapy have become the reference treatment in first-line metastatic HR+ HER2- breast cancer, based on published clinical data on efficacy and survival.
In this context, a specific e-learning on the care pathway of metastatic HR+ HER2- breast cancer has been developed in order to :
to shed light on the epidemiology of HER2-positive metastatic breast cancer in France and on the evolution of recommendations since 2015
redefine the role of hormone therapy as an alternative to chemotherapy, including in the case of visceral metastases and in the absence of severe organ failure
to clarify the role of CDK4/6 inhibitors in combination with hormone therapy in the first line of treatment and the available efficacy data
to clarify the choice of hormone therapy to be combined with CDK4/6 inhibitors.
Healthcare professionals have access to an initial and final 8-question quiz to test their knowledge and evaluate their progress, followed by 2 expert videos:
Dr Christelle Levy, Head of the Institut Normand du Sein Centre François Baclesse (Caen) who will discuss the strategy of combining anti-CDK4/6 + HT in first line: the standard of care;
Dr. Jean-Sébastien Frénel, Institut de Cancérologie de l'Ouest (Saint Herblain) who answers the question "which hormone therapy in association with anti-CDK4/6 in first line? ".
This e-learning course, produced with the institutional support of Pfizer, is now available free of charge in one click on VIDAL Campus, for any healthcare professional practicing in France (working, student, retired) with a VIDAL account.